Literature DB >> 20715112

Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.

Ricardo Fernández-Ramires1, Gonzalo Gómez, Iván Muñoz-Repeto, Loris de Cecco, Gemma Llort, Alicia Cazorla, Ignacio Blanco, Manuela Gariboldi, Marco Alessandro Pierotti, Javier Benítez, Ana Osorio.   

Abstract

To better understand the alterations present in the group of the so-called BRCAX tumors, we have used a cDNA microarray containing genes related to tumorigenesis and analyzed a series of 49 tumors consisting of 13 BRCA1, 14 BRCAX and 22 sporadic. We have confirmed that the BRCAX tumors are heterogeneous and can be divided in at least two main subgroups, so-called A and B, transcriptionally distinguishable and with different altered pathways within each of the groups. We have found that BRCAX-A and B subgroups, can be classified as Luminal A and Luminal B, respectively, taking into account the intrinsic phenotypes defined for the sporadic breast tumors. We have found that, at the somatic level, the BRCAX-B tumors are identical to their sporadic Luminal B counterparts, whereas BRCAX-A, despite having a Luminal A phenotype, shows additional genomic alterations. We have found 21 deregulated genes in the BRCAX-A group that we have called "the BRCAX susceptibility pathway" and suggested it as a candidate to search for new genes involved in the inherited susceptibility underlying the disease in this group.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715112     DOI: 10.1002/ijc.25603

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Single-base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes.

Authors:  Bradley Downs; Fengxia Xiao; Yeong C Kim; Pei Xian Chen; Dali Huang; Elizabeth A Fleissner; Kenneth Cowan; San Ming Wang
Journal:  Breast J       Date:  2017-01-24       Impact factor: 2.431

Review 2.  The complex genetic landscape of familial breast cancer.

Authors:  Lorenzo Melchor; Javier Benítez
Journal:  Hum Genet       Date:  2013-04-05       Impact factor: 4.132

Review 3.  Hereditary breast cancer: clinical, pathological and molecular characteristics.

Authors:  Martin J Larsen; Mads Thomassen; Anne-Marie Gerdes; Torben A Kruse
Journal:  Breast Cancer (Auckl)       Date:  2014-10-15

4.  VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.

Authors:  Concetta Saponaro; Andrea Malfettone; Girolamo Ranieri; Katia Danza; Giovanni Simone; Angelo Paradiso; Anita Mangia
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

5.  RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.

Authors:  Martin J Larsen; Mads Thomassen; Qihua Tan; Anne-Vibeke Lænkholm; Martin Bak; Kristina P Sørensen; Mette Klarskov Andersen; Torben A Kruse; Anne-Marie Gerdes
Journal:  BMC Med Genomics       Date:  2014-01-31       Impact factor: 3.063

6.  MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.

Authors:  M Tanic; E Andrés; S M Rodriguez-Pinilla; I Marquez-Rodas; M Cebollero-Presmanes; V Fernandez; A Osorio; J Benítez; B Martinez-Delgado
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

7.  MicroRNAs discriminate familial from sporadic non-BRCA1/2 breast carcinoma arising in patients ≤35 years.

Authors:  Elen Pereira Bastos; Helena Brentani; Fatima Solange Pasini; Aderbal Ruy T Silva; Cesar Henrique Torres; Renato David Puga; Eloisa Helena Ribeiro Olivieri; Amanda Rusiska Piovezani; Carlos Alberto de Bragança Pereira; Ariane Machado-Lima; Dirce Maria Carraro; Maria Mitzi Brentani
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

8.  Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families.

Authors:  Marie-Christine Pouliot; Charu Kothari; Charles Joly-Beauparlant; Yvan Labrie; Geneviève Ouellette; Jacques Simard; Arnaud Droit; Francine Durocher
Journal:  Oncotarget       Date:  2017-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.